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Elderly in clinical trials
a  b  s  t  r  a  c  t
Aim: The analysis of barriers responsible for low recruitment of older patients in clinical
trials and presentation of possible solutions are the subject of this review.
Background: Europe’s population is ageing, and the group of people who more  frequently
develop neoplasms increases. Oncologists are confronted with a new challenge – how to
treat cancer in this group of patients, especially considering the lack of Evidence Based
Medicine (EBM) guidelines for treatment of cancer in the elderly population.
Materials and methods: Medline search and analysis of studies published between 1999 and
2012,  containing key words: senior adults, cancer, elderly in clinical trials.
Results: Detailed analysis of relevant studies demonstrated that senior adults are under-
represented in clinical trials. Moreover, there is a lack of trials exclusively designed for
this heterogeneous group of patients. The analysis of reasons for low recruitment of older
patients in clinical trials revealed barriers dependent on patient’s and physician’s attitudes
as  well as institutional and logistic problems.
Conclusions: It is necessary to widen the scale of trials of all phases in the group of seniorswith appropriate assessment of toxicity. This will allow a proper stratiﬁcation and obtaining
representative groups for statistical analysis and credible trial results. Another priority is
the design of trials dedicated exclusively to the elderly.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
unsatisfactory. A case in point here is the group of elderly1.  Background
A well-designed randomised clinical trial (RTC) constitutes
one of the most important methods of testing therapeutic
hypotheses and provides level I evidence for the justiﬁca-
tion of a therapeutic process.1 Such trials form the basis of
meta-analysis which underlies the standards of treatment and
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enables patients to be treated following the guidelines of Evi-
dence Based Medicine (EBM). However, if one analysed the
groups of patients included in RTC in oncology, it would turn
out that the representation of certain groups in the trials isancer Center, Garbary St 15, Poznan, Poland. Tel.: +48 61 8850 750;
patients which, according to an arbitrary deﬁnition, encom-
passes people aged over 65. Prevalence of particular cancers
in senior adults is different than in younger population. Most
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requently diagnosed cancer in people over 65 is prostate can-
er followed by colorectal cancer as well as brain and breast
ancer.2 As research demonstrates, only 22% of patients over
5 participate in all cancer clinical trials and among people
ged over 70 the percentage falls to a mere  8%.3–6 Signiﬁ-
ant differences were demonstrated between participation in
ancer site-speciﬁc trials. Lewis et al. demonstrated in their
eta-analysis that the elderly were signiﬁcantly underrepre-
ented in phase III melanoma, breast, colorectal, head and
eck, lung, central nervous system and uterine cancer trials.6
enior population was adequately represented in early and
ate prostate cancer related trials and especially in breast can-
er hormonal treatment trials.6,7
This problem is receiving more  and more  interest as it con-
erns a growing number of patients – Europe’s population is
geing at an ever faster rate.8 Thus, oncologists are confronted
ith a new challenge – how to treat cancer in this group of
atients. Due to the lack of data concerning the treatment
f older cancer patients, this group is often excluded from
tandard aggressive treatment, especially adjuvant. What is
ore, senior patients form a considerably heterogeneous
roup – following solely the criterion of age results in having
oth ﬁt as well as vulnerable and frail individuals in the same
roup. Hence, it is not possible to refer to this group the results
btained in the group of younger persons, which is relatively
omogeneous in terms of health status.
The multidimensionality of the problem is responsible for
he fact that physicians are not only unwilling to include the
lderly in ongoing clinical trials but they are also afraid to
pply standard treatment, especially adjuvant, considering it
o be too aggressive. Aparicio’s research in which he proved
hat 52% of patients with colorectal cancer had sub-standard
reatment can serve as an illustrating example.11
However, it is the adjuvant therapy that has a positive
ffect on the survival rate and the time to recurrence in the
ase of patients with resected colon cancer.12 Folprecht pre-
ented similar results concerning the treatment of metastatic
olorectal cancer by means of standard chemotherapy 5FU:
he survival rates in the case of older patients were compa-
able to those of younger ones.13 Likewise, the application
f standard, more  aggressive adjuvant treatment in women
ith breast cancer who  were over 65 proved superior to less
ggressive treatment in the context of survival.14 The results
f the research indicate that a signiﬁcant number of senior
atients derive signiﬁcant beneﬁt from more  aggressive meth-
ds. Thus, seniors should also be included in experimental
linical trials, provided that their health state, physiological
eserves, and comorbidities will be correctly assessed.
Recently, the National Comprehensive Cancer Network
NCCN) and the European Organisation for Research and Treat-
ent of Cancer (EORTC) issued ﬁrst recommendations for
reatment of senior adults.9,10
.  Aimhe analysis of barriers responsible for the underrepresenta-
ion of older patients in clinical trials and the design of clinical
rials dedicated exclusively to seniors will be the subject of this
eview.diotherapy 1 8 ( 2 0 1 3 ) 6–10 7
3.  Materials  and  methods
Medline search of peer reviewed studies published between
1999 and 2012 containing keywords: senior adults, cancer,
elderly in clinical trials. Reference lists from relevant studies
were scanned to identify any additional studies.
Studies included in the review were in English; reports pub-
lished in the form of abstracts were not included.
Studies reporting reasons or barriers of underrepresenta-
tion of seniors in clinical trials of all phases and analysing
potential solutions were included into the analysis. Studies
without analysis for reasons of recruitment barriers or ones
that reported on the absence of all minorities beyond elderly
only trials were excluded.
4.  Results
Medline search identiﬁed 13,900 publications evaluating
seniors’ representation in cancer clinical trials, 106 exploring
underrepresentation of elderly in clinical trials. 13 relevant
papers analysed and discussed barriers and solutions in
recruiting patients over 65 years in research studies.
Reasons for the underrepresentation of elderly in clinical
trials could be divided into system-, physician- and patient-
dependent15 and are described below.
4.1.  Eligibility  criteria  and  trial  design.
Until recently, it seemed that one of the basic causes of the
underrepresentation of older patients in clinical trials was
strict eligibility criteria which speciﬁed the maximum age of
patients included in the trials. In general, the maximum age
for many  trials was 65 or 70 years. Nevertheless, the Cancer
and Leukaemia Group B (CALBG) trial did not fully conﬁrm
this phenomenon – in the trial of adjuvant chemotherapy in
breast cancer where there was no age limit, only 8% of female
patients included were older than 65 and only 4% were over
70 years of age.16 In 1989, the FDA recommended not exclud-
ing older patients from clinical trials as age in itself cannot be
regarded as an eligibility criterion.17
Also, seniors are much more  often included in cancer tri-
als which look at the late stage of cancer than in early-stage
cancer trials.6 Another alarming observation is that the per-
centage of elderly patients is small not only in the case of trials
concerning basic treatment but also in the trials investigating
supportive care – 24% and 21%, respectively.4 The other factors
excluding patients from clinical trials are comorbid illnesses
and functional status.
4.2.  Functional  status  and  comorbidities
The natural processes of ageing inﬂuence the functions of
many organs and many  physiological processes, which in turn
can affect negatively the results of trials.Many trials exclude patients with kidney and liver dysfunc-
tions as well as cardiac failure, which are typical of old age.
Such exclusion criteria lower signiﬁcantly the participation of
elderly patients in clinical trials – by about 22%.18 Moreover,
nd r8  reports of practical oncology a
clinicians themselves are unwilling to propose new experi-
mental treatment which may, because of its toxicity, worsen
the state of the already frail patient.19 Such concerns are often
justiﬁed, but the assessment of the actual health condition of
the senior is a complex matter and cannot be made following
only a subjective evaluation of the clinician. Comprehensive
Geriatric Assessment (CGA) seems to be the most suitable
instrument of thorough evaluation of senior’s health.20
Comorbid illnesses are an inextricable part of the treatment
of older cancer patients.21 On average, they suffer from 5 co-
existing illnesses, including the most frequent cardiovascular
and respiratory diseases.22 Since in many  cases we still have
too little information about the tolerance of treatment when
comorbidities are present, it is necessary to design clinical tri-
als in such a way as to allow for a reliable assessment of the
inﬂuence these conditions have on the results of treatment
and its toxicity and vice versa. Illnesses which impair func-
tioning at old age do not necessarily inﬂuence in the same
way the results of various oncological treatment methods.
Advanced coxarthrosis can serve as an example – it does not
affect chemotherapy in a signiﬁcant way but it may seriously
impair the reproducibility of positioning in radiotherapy of the
pelvis and increase the risk of serious late effects. In addition,
some trials still exclude patients who  had cancer in the past,
which much more  often concerns older patients.
4.3.  Polypharmacy  and  drug  interactions
Because of numerous comorbidities, many  elderly patients
take regularly on average 6 medications a day and the ten-
dency is increasing.23 The medications taken may interact
with oncological drugs, intensify or weaken their effect as well
as cause unpredictable severe adverse effects. Therefore, the
ﬁrst step when including a patient in a clinical trial should
be a rational reduction of the number of medications by an
experienced geriatrician.
4.4.  Patients’  preferences
Patients’ preferences and their possible reluctance to partici-
pate in the phase I and II trials were presented by Basche and
colleagues on the basis of a survey conducted in the senior
groups aged 65–74 and 75 and over. The survey revealed that
over 40% of seniors do not perceive any obstacles to their par-
ticipation in such trials.
The main causes of the reluctance to participate reported
by the patients were the logistic issues: the necessary time
and assistance required of another person, the necessity to
undergo treatment in an academic centre far from their place
of residence as well as discontinuation of the treatment by
their “own”, well known, primary oncologists. Incorporating
primary oncologists into the trials was an important con-
dition for 100% of respondents participating in the survey.
Seniors, especially older ones, are willing to accept possible
side effects of the trial, in particular nausea and vomiting to
a lesser extent.24 It seems, thus, that the obstacles stemming
from patients’ incertitude are relatively easy to eliminate, e.g.
by visiting patients at their homes or organizing transport
and care for them, incorporating their primary oncologist and
nurse in the trials, providing best supportive care in order toadiotherapy 1 8 ( 2 0 1 3 ) 6–10
minimise the negative side effects or the toxicity of exper-
imental treatment. An essential issue for the patients was
also appropriate information concerning the proposed trial,
adjusted to the patients’ perception.
4.5.  Physician’s  factors
It turns out that a number of seniors regardless of their prefer-
ences and potential are not offered a chance of participation
in clinical trials. A partial explanation of this situation is pro-
vided by the survey conducted by Kornbilth and colleagues.
There are a number of reasons for physicians’ reluctance
to include older patients in clinical trials. The major ones
include: the concern about excessive toxicity and comorbidi-
ties as well as insufﬁcient, in the physician’s view, support at
patient’s home, expected difﬁculties with understanding the
assumptions of clinical trials by patients and greater amount
of time necessary to explain the trial to a senior patient.
Another signiﬁcant factor here is logistics: e.g. transportation
of a patient to a centre and expected poor compliance. More-
over, a number of health professionals are of the opinion that
short survival time should exclude patients from participation
in clinical trials.25
An additional factor was physicians’ lack of knowledge
about the availability of a suitable clinical trial for an indi-
vidual patient. These barriers appear to be relatively easy to
overcome by dissemination of information concerning clini-
cal trials among physicians and providing appropriate social
and logistic support. On the other hand, the assessment of
health status and the reserves of the organism as well as the
expected toxicity require collaboration with geriatrician and
application of tests and scales dedicated to this assessment.
4.6.  Treatment  toxicity
The expected excessive toxicity is one of the main reasons
why older patients are excluded from clinical trials, in partic-
ular the trials where new experimental drugs or radiotherapy
treatment are used. Pharmacokinetics of medications taken by
older patients varies from the group of younger persons as well
as from senior to senior. It is linked to changes in organs and
physiological processes which occur in old age. These changes
in organs lead to different bioavailability of drugs, especially
oral drugs and the decrease in the effectiveness of medications
which are activated by liver enzymes. Additionally, kidneys
function as well as the rate at which drugs are removed from
the organism have a signiﬁcant inﬂuence on the expected tox-
icity of the therapy.26 Also the interactions of tested drugs with
medications used for comorbid illnesses are important. This
results in clinicians’ concerns about the unexpected adverse
effects of new therapies in older patients, particularly in the
case of completely new targeted therapies and their experi-
mental combination with radiotherapy, for example, although
evidence exists that senior patients can tolerate molecular
targeted therapies as well as younger counterparts.27
Adjuvant treatment in seniors constitutes a separate prob-
lem as it is frequently considered too toxic for older patients.
However, as research demonstrated in the case of solid
tumours, such as colorectal or lung cancer,12,13 older patients
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o the group of younger patients, while beneﬁcial effects on
heir overall survival were noted. In order to overcome clini-
ians’ views regarding the excessive toxicity of treating older
eople, it is necessary to carry out a detailed study on dose
elated toxicity and drug interaction, as well as to conduct a
ell-designed stratiﬁcation in trials according to functional
tatus, comorbidities and potential dose modiﬁcation.
.7.  Supportive  care
upportive care in its wide sense is an indispensable element
f modern oncological treatment. Elderly patients, particu-
arly frail, should be provided with thorough care because the
uccess of the trial frequently depends on supportive care.
or instance, intense vomiting may cause dehydration and
lectrolyte disturbance; oral mucositis can lead to food aver-
ion, hypoalbuminemia, malnutrition, etc. Likewise, anaemia
nd/or leucopenia may result in treatment failures due to
ypoxia and infections. Understanding the signiﬁcance of
upportive care during treatment may considerably inﬂuence
he perception of toxicity by clinicians and, thus, encourage
hem to include older patients in clinical trials.
. Discussion
n the face of the ageing of societies of Europe and other
ontinents, developing both guidelines and therapeutic rec-
mmendations for the growing group of senior patients
ssumes signiﬁcance. Are we as oncologists prepared for this?
nfortunately, the lack of knowledge concerning not only
etailed physiology of ageing but also cancer itself is the
eason why we  practically do not have guidelines for such
 heterogeneous group of patients as senior adults. Clinical
rials constitute the foundation for creating guidelines compli-
nt with the EBM. However, as the representation of the elderly
opulation in clinical trials is too small because of reasons dis-
ussed above, it is not possible to draw important conclusions
or this group of patients. Moreover, biological and physiolog-
cal differences do not allow to apply the results of younger
atients directly to the group of the elderly. Therefore, it is
ital to include senior adults in ongoing trials preceded by a
etailed and credible assessment of older patients’ health sta-
us. It is equally or maybe even more  important to design trials
edicated exclusively to seniors, taking into consideration
unctional, biological and social factors. A number of orga-
isations conducting large scale cross-centre research have
lready begun to investigate this problem. The EU7 project
ntitled “Increasing the Participation of the Elderly In Clinical
rials” (PREDICT) investigated the reasons for the exclusion
f senior adults from clinical trials not only in oncology but
lso in internal medicine and proposed solutions for this
roblems.28
Another example is work of the Elderly Task Force, which
as created within the framework of the European Organi-
ation for Research and Treatment of Cancer (EORTC). This
roup of specialists is responsible for developing method-
logy of conducting clinical trials with the participation of
eniors. Tools recommended for screening health status of
lderly patients have been suggested. They allow to categorisediotherapy 1 8 ( 2 0 1 3 ) 6–10 9
patients into ﬁt and frail as well as assess the functional
reserves of an individual patient. The proposed set of instru-
ments – Minimal Data Set (MinDS) – contains such tools as
Instrumental Activities of Daily Living scale (IADL), G8, Charl-
son Comorbidity Index (CCI) and the evaluation of patient’s
social situation.
The recommendations also stress that besides the classic
endpoints of a clinical trial, the emphasis should be put on
assessing the inﬂuence of tested treatment on the quality of
life (QoL), independence and functional status of seniors. Fur-
thermore, a panel of experts recommended such collaboration
with the pharmaceutical industry in which post-marketing
studies would be obligatory for vulnerable older patients and
suggested a detailed analysis of age groups in planned trials.
Also, the International Society of Geriatrics (SIOG) in its plans
for the nearest future stresses the signiﬁcance of development
of senior studies.29
6. Conclusions
It is necessary to widen the scale of phases I and II trials in the
group of seniors with appropriate assessment of toxicity as
well as to include larger groups of older patients in the phase
III trials. This will allow a proper stratiﬁcation and obtain-
ing representative groups for statistical analysis and credible
trial results. Another priority is the design of trials dedicated
exclusively to the elderly.
The presented data suggest that the situation of older peo-
ple diagnosed with cancer is improving and the awareness of
the problem which we  will soon face – be it as oncologists or
as patients over 65 years of age – is growing.
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